Viviana Vélez-Marín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Viviana Vélez-Marín has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Felipe Patiño-Lugo
Universidad de Antioquía
4 shared publications - Claudia Marcela Vélez
Faculty of Medicine, University of Antioquia, Medellín, Colombia
2 shared publications - Ivan Dario Florez
Department of Pediatrics, University of Antioquia, Medellin, Colombia
2 shared publications - Juan Camilo Martínez
Unit of Evidence and Deliberation for Decision Making UNED, Medical Research Institute, School of Medicine, University of Antioquia, Medellin, Colombia
2 shared publications - Mary Lopez-Perez
Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen
2 shared publications - Ana María Pérez-Gutiérrez
Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada, Spain
1 shared publication
Latest Publications
- Open Access
- 2 November 2024
- Published by Springer Nature in Malaria Journal
- Vol. 23 (1) , 1-11
Diagnostic accuracy of the point-of-care standard G6PD test™ (SD Biosensor) for glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis
Background: Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic enzymopathy that can induce haemolysis triggered by various factors, including some anti-malarial drugs. Although many Point-of-Care (PoC) tests, such as Standard G6PD™ are available to detect G6PDd, its pooled diagnostic test accuracy (DTA) remains unknown. Methods: To estimate the DTA of StandG6PD-BS at various thresholds of G6PDd, a systematic review with a DTA meta-analysis were conducted, searching EMBASE, MEDLINE, and SciELO databases up to April 4, 2024.The included studies were those that measured G6PD activity using StandG6PD-BS (reference test) and spectrophotometry (gold standard) in patients suspected of having G6PDd. The risk of bias (RoB) of the studies was assessed using the QUADAS-2 tool and the certainty of evidence (CoE) with the GRADE approach. For the estimation of within-study DTA, a random-effect bivariate meta-analysis was performed to determine the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels’ thresholds, and a graphical analysis of the heterogeneity using crosshair and Confidence Regions on receiver operating characteristic (ROC) space plots. Results: After screening 2496 reports, four studies were included with 7864 participants covering all thresholds. Two studies had high RoB in QUADAS-2 domains 2 and 3, and the others had low RoB, with low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity was 99.1%, 95.7%, and 90% for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was 97.4%; 92.9%; and 89.0% for 30%, 70%, and 80% thresholds, respectively. Conclusion: StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.
- 2 November 2024
- Published by Springer Nature in Malaria Journal
- Vol. 23 (1) , 1-11
Open AccessDiagnostic accuracy of the point-of-care standard G6PD test™ (SD Biosensor) for glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis
Background: Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic enzymopathy that can induce haemolysis triggered by various factors, including some anti-malarial drugs. Although many Point-of-Care (PoC) tests, such as Standard G6PD™ are available to detect G6PDd, its pooled diagnostic test accuracy (DTA) remains unknown. Methods: To estimate the DTA of StandG6PD-BS at various thresholds of G6PDd, a systematic review with a DTA meta-analysis were conducted, searching EMBASE, MEDLINE, and SciELO databases up to April 4, 2024.The included studies were those that measured G6PD activity using StandG6PD-BS (reference test) and spectrophotometry (gold standard) in patients suspected of having G6PDd. The risk of bias (RoB) of the studies was assessed using the QUADAS-2 tool and the certainty of evidence (CoE) with the GRADE approach. For the estimation of within-study DTA, a random-effect bivariate meta-analysis was performed to determine the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels’ thresholds, and a graphical analysis of the heterogeneity using crosshair and Confidence Regions on receiver operating characteristic (ROC) space plots. Results: After screening 2496 reports, four studies were included with 7864 participants covering all thresholds. Two studies had high RoB in QUADAS-2 domains 2 and 3, and the others had low RoB, with low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity was 99.1%, 95.7%, and 90% for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was 97.4%; 92.9%; and 89.0% for 30%, 70%, and 80% thresholds, respectively. Conclusion: StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.
- Open Access
Diagnostic accuracy of the Point-of-Care Standard G6PD test™ (SD Biosensor) for Glucose-6-phosphate dehydrogenase deficiency: a systematic review of the literature
Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic enzymopathy that can induce hemolysis triggered by various factors, including some anti-malarial drugs. Although many Point-of-Care (PoC) tests, such as STANDARD G6PD TM manufactured by SD biosensor (StandG6PD-BS), are available to detect G6PDd, its pooled diagnostic test accuracy (DTA) remains unknown. To estimate the DTA of StandG6PD-BS at various thresholds of G6PDd, we conducted a systematic review with a DTA meta-analysis, searching EMBASE, MEDLINE, and SciELO databases up to June 30, 2023. We included studies measuring G6PD activity using StandG6PD-BS (reference test) and spectrophotometry (gold standard) in patients suspected of having G6PDd. We assessed the risk of bias (RoB) of the studies using the QUADAS-2 tool and the certainty of evidence (CoE) with the GRADE approach. Our approach included the estimation of within-study DTA, a random-effect bivariate meta-analysis to determine the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels’ thresholds, and a graphical analysis of the heterogeneity using crosshair and Confidence Regions on receiver operating characteristic (ROC) space plots. After screening 2,407 reports, we included four studies with 7,864 participants covering all thresholds. Two studies had high RoB in QUADAS-2 domains 2 and 3, and the others had low RoB. We also found low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity was 99.1% (95%CI 96.9-99.7%, CoE: high), 95.7% (92.0-97.0%, high), and 90% (78.0-96.5%, low) for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was 97.4% (95%CI 95.0; 98.4%, high); 92.9% (85.0-96.4%, high); and 89.0% (76.0-96.0%, moderate) for 30%, 70%, and 80% thresholds, respectively. In conclusion, StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds. Author summary: Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic disease that can induce the destruction of red blood cells leading to anemia triggered by various factors, including some drugs used for malaria treatment. After a literature search in different databases up to January 31, 2023, we pooled diagnostic test accuracy of the Point-of-Care (PoC) STANDARD G6PDTM test manufactured by SD biosensor (StandG6PD-BS) used to identify the G6PDd. Although two of the four studies included showed a high Risk of Bias related to the index test and the reference standard domains of the QUADAS-2 tool, the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels’ thresholds were around 90%, with better sensitivity and specificity values for the 30% threshold (99.1% and 97.4%) compared with 70% (95.7% and 92.9%) and 80% (90% and 89%) threshold. We found low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds. In conclusion, StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.
Open AccessDiagnostic accuracy of the Point-of-Care Standard G6PD test™ (SD Biosensor) for Glucose-6-phosphate dehydrogenase deficiency: a systematic review of the literature
Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic enzymopathy that can induce hemolysis triggered by various factors, including some anti-malarial drugs. Although many Point-of-Care (PoC) tests, such as STANDARD G6PD TM manufactured by SD biosensor (StandG6PD-BS), are available to detect G6PDd, its pooled diagnostic test accuracy (DTA) remains unknown. To estimate the DTA of StandG6PD-BS at various thresholds of G6PDd, we conducted a systematic review with a DTA meta-analysis, searching EMBASE, MEDLINE, and SciELO databases up to June 30, 2023. We included studies measuring G6PD activity using StandG6PD-BS (reference test) and spectrophotometry (gold standard) in patients suspected of having G6PDd. We assessed the risk of bias (RoB) of the studies using the QUADAS-2 tool and the certainty of evidence (CoE) with the GRADE approach. Our approach included the estimation of within-study DTA, a random-effect bivariate meta-analysis to determine the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels’ thresholds, and a graphical analysis of the heterogeneity using crosshair and Confidence Regions on receiver operating characteristic (ROC) space plots. After screening 2,407 reports, we included four studies with 7,864 participants covering all thresholds. Two studies had high RoB in QUADAS-2 domains 2 and 3, and the others had low RoB. We also found low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity was 99.1% (95%CI 96.9-99.7%, CoE: high), 95.7% (92.0-97.0%, high), and 90% (78.0-96.5%, low) for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was 97.4% (95%CI 95.0; 98.4%, high); 92.9% (85.0-96.4%, high); and 89.0% (76.0-96.0%, moderate) for 30%, 70%, and 80% thresholds, respectively. In conclusion, StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds. Author summary: Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic disease that can induce the destruction of red blood cells leading to anemia triggered by various factors, including some drugs used for malaria treatment. After a literature search in different databases up to January 31, 2023, we pooled diagnostic test accuracy of the Point-of-Care (PoC) STANDARD G6PDTM test manufactured by SD biosensor (StandG6PD-BS) used to identify the G6PDd. Although two of the four studies included showed a high Risk of Bias related to the index test and the reference standard domains of the QUADAS-2 tool, the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels’ thresholds were around 90%, with better sensitivity and specificity values for the 30% threshold (99.1% and 97.4%) compared with 70% (95.7% and 92.9%) and 80% (90% and 89%) threshold. We found low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds. In conclusion, StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.
- Open Access
- 1 January 2024
- Published by Universidad de Antioquia in Revista Facultad Nacional de Salud Pública
- Vol. 42 (42) , e356278
Las tensiones sobre qué incluir y a quién cubrir en el sistema de salud colombiano desde la perspectiva de un grupo de ciudadanos
Objetivo: Esta investigación pretende explorar y comprender las percepciones de un grupo de ciudadanos sobre las tecnologías y los servicios en salud que deben financiarse con recursos públicos. Métodos: Se utilizó un estudio de caso cualitativo. Se recolectó información mediante entrevistas semiestructuradas a 46 participantes en cinco grupos poblacionales (personas sin contacto reciente con servicios de salud, pacientes, trabajadores de la salud, administradores y tomadores de decisiones). Posteriormente, se realizó un análisis temático. Resultados: Se identificaron dos aproximaciones para llevar a cabo la financiación de tecnologías y servicios en salud con recursos públicos: una aproximación la condiciona a 1) las características de quién necesita la atención, 2) la enfermedad que padece, 3) la tecnología o servicio requerido, y 4) la expectativa de desempeño eficiente del sistema de salud, determinando la cobertura por las condiciones económicas y la vulnerabilidad social de la persona, la urgencia de la atención o la evidencia de efectividad. La otra aproximación considera la cobertura total de las tecnologías y los servicios para todos los colombianos, basada en principios de dignidad humana, derecho a la salud y uso honrado de los recursos. Conclusiones: Las aproximaciones identificadas responden a tensiones sociales relativas a la estructura del sistema de salud y su organización en la prestación de servicios. Las tres tensiones más importantes son aquellas relacionadas con la capacidad económica del ciudadano, la perspectiva que define el concepto salud-enfermedad, y los significados de efectividad y evidencia científica.
- 1 January 2024
- Published by Universidad de Antioquia in Revista Facultad Nacional de Salud Pública
- Vol. 42 (42) , e356278
Open AccessLas tensiones sobre qué incluir y a quién cubrir en el sistema de salud colombiano desde la perspectiva de un grupo de ciudadanos
Objetivo: Esta investigación pretende explorar y comprender las percepciones de un grupo de ciudadanos sobre las tecnologías y los servicios en salud que deben financiarse con recursos públicos. Métodos: Se utilizó un estudio de caso cualitativo. Se recolectó información mediante entrevistas semiestructuradas a 46 participantes en cinco grupos poblacionales (personas sin contacto reciente con servicios de salud, pacientes, trabajadores de la salud, administradores y tomadores de decisiones). Posteriormente, se realizó un análisis temático. Resultados: Se identificaron dos aproximaciones para llevar a cabo la financiación de tecnologías y servicios en salud con recursos públicos: una aproximación la condiciona a 1) las características de quién necesita la atención, 2) la enfermedad que padece, 3) la tecnología o servicio requerido, y 4) la expectativa de desempeño eficiente del sistema de salud, determinando la cobertura por las condiciones económicas y la vulnerabilidad social de la persona, la urgencia de la atención o la evidencia de efectividad. La otra aproximación considera la cobertura total de las tecnologías y los servicios para todos los colombianos, basada en principios de dignidad humana, derecho a la salud y uso honrado de los recursos. Conclusiones: Las aproximaciones identificadas responden a tensiones sociales relativas a la estructura del sistema de salud y su organización en la prestación de servicios. Las tres tensiones más importantes son aquellas relacionadas con la capacidad económica del ciudadano, la perspectiva que define el concepto salud-enfermedad, y los significados de efectividad y evidencia científica.
- Open Access
- 1 July 2021
- Published by Elsevier in Revista Colombiana de Psiquiatria (english Ed.)
- Vol. 50 (3) , 199-213
Mental health interventions for college and university students during the COVID-19 pandemic: A critical synthesis of the literature
- 1 July 2021
- Published by Elsevier in Revista Colombiana de Psiquiatria (english Ed.)
- Vol. 50 (3) , 199-213
Open AccessMental health interventions for college and university students during the COVID-19 pandemic: A critical synthesis of the literature